Crinetics Pharmaceuticals Stock Price, News & Analysis

Crinetics Pharmaceuticals (Nasdaq: CRNX) reported Q2 2025 financial results and significant progress across its endocrine disease pipeline. The company's lead candidate PALSONIFY™ (paltusotine) has a PDUFA date of September 25, 2025, for acromegaly treatment. Q2 financial highlights include $1.2B in cash providing runway into 2029, revenues of $1.0M, and a net loss of $115.6M.

The company is advancing multiple clinical programs, including atumelnant's global development with the BALANCE-CAH Phase 2/3 pediatric study planned for 2025. The EMA validated paltusotine's MAA for acromegaly with a potential decision in H1 2026. R&D expenses increased to $80.3M, while SG&A expenses rose to $49.8M, reflecting expansion of clinical programs and commercial preparation efforts.

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced new long-term data for PALSONIFY™ (paltusotine), their investigational once-daily oral treatment for acromegaly, to be presented at ENDO 2025. The data comes from open-label extensions of two Phase 3 trials: PATHFNDR-1 and PATHFNDR-2.

Key findings through Week 96 show that PALSONIFY maintained stable IGF-1 levels in patients who switched from injectable treatments, with mean IGF-1 levels of 0.81 times the upper limit of normal. In PATHFNDR-2, patients showed sustained IGF-1 reductions, with a mean change of -0.81 × ULN at Week 84. The drug demonstrated durable biochemical control, reduced symptom burden, and was generally well-tolerated across both studies.

Crinetics Pharmaceuticals (NASDAQ:CRNX) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, after market close. The company will host a conference call at 4:30 p.m. ET featuring management discussion of financial results and a business update.

Investors can participate via phone using domestic (1-833-470-1428) or international (1-404-975-4839) dial-in numbers with access code 899803, or through a live webcast available on the company's website. Participants are advised to connect 15 minutes before the call, and a webcast replay will be available in the Investor Relations section of www.crinetics.com.

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced new equity grants under its 2021 Employment Inducement Incentive Award Plan. The company granted 102,350 non-qualified stock options and 77,875 restricted stock units (RSUs) to 46 new non-executive employees.

The stock options have an exercise price of $31.99 per share, equal to CRNX's closing price on July 10, 2025. Both options and RSUs will vest over four years, with options having a 25% first-year cliff and monthly installments thereafter, while RSUs vest in equal annual installments.

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced it will present eight abstracts from its clinical development programs at ENDO 2025, taking place July 12-15, 2025, in San Francisco. The presentations will showcase data from multiple drug candidates across their endocrinology pipeline.

Key highlights include long-term efficacy and safety data for PALSONIFY™ (paltusotine) in acromegaly, featuring four abstracts demonstrating consistent biochemical and symptom control in patients. The company will present Phase 2 trial results for atumelnant in congenital adrenal hyperplasia (CAH) through three abstracts, including data on adrenal volume reduction and androgens reduction.

Additionally, Crinetics will present new data from its early-stage pipeline, including CRN12755 for Graves' hyperthyroidism and orbitopathy. The company will also host two sponsored science and innovation theaters focusing on acromegaly management.

Crinetics Pharmaceuticals (NASDAQ: CRNX) has announced an upcoming R&D Day event scheduled for June 26, 2025, from 9:00 AM to 12:00 PM ET in New York, with both in-person and virtual attendance options. The event will showcase updates on the company's early-stage pipeline assets, development strategies, and plans for long-term value creation. Key presentation topics will include their NDC platform with CRN09682 for NETs and beyond, TSH antagonist developments for Graves' disease and thyroid eye disease (TED), and SST3 agonist research for autosomal polycystic kidney disease (ADPKD). The event will conclude with a live Q&A session.

Crinetics Pharmaceuticals (CRNX) has granted equity-based compensation to 20 new non-executive employees on June 10, 2025. The compensation package includes 74,000 non-qualified stock options with an exercise price of $33.08 per share and 48,850 restricted stock units (RSUs). The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest in equal annual installments over four years. These awards were granted under the company's 2021 Employment Inducement Incentive Award Plan, specifically designed for new hires in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals (NASDAQ: CRNX) has announced its participation in the upcoming Jefferies Global Healthcare Conference 2025, scheduled for June 3-5, 2025 in New York. The company's management will deliver a presentation on Thursday, June 5, 2025, at 12:50 p.m. Eastern Time. Investors can access the live and archived webcast through the Events & Presentations page in the Investors section of Crinetics' website. One-on-one meetings with management can be arranged through conference representatives.

Crinetics Pharmaceuticals (NASDAQ: CRNX) will present new research on its investigational drugs at the AACE Annual Meeting 2025 in Orlando. Key highlights include: 1. A post-hoc analysis showing paltusotine, their lead candidate, demonstrated rapid and durable IGF-1 control in surgically naïve acromegaly patients, with positive results: - 3/4 patients in PATHFNDR-1 and all 4 in PATHFNDR-2 achieved IGF-1 normalization - Median IGF-1 remained stable over 24 months in ACROBAT Advance 2. Research on symptom burden showing patients on current injectable treatments experience symptom exacerbations on 32% of days. 3. Real-world evidence revealing 54% of acromegaly patients discontinue current standard therapy. The company awaits a PDUFA date of September 25 for paltusotine in the U.S., with regulatory reviews progressing in both U.S. and EU.